Peptides Market By Application(Metabolic Disorders, Cancer, Cardiovascular Disorders, Respiratory Disorders, Others), By Type(Branded, Generic), By Type of Manufacturers(In-house, Outsourced), By Route of Administration(Parenteral Route, Oral Route, Pulmonary,Others), By Synthesis Technology(Liquid Phase Peptide Synthesis, Solid Phase Peptide Synthesis, Hybrid Technology), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2024-2033
-
43000
-
Jan 2024
-
179
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Peptides Market Size, Share, Trends Analysis
The peptides market was valued at USD 45.5 billion in 2023. It is expected to reach USD 89.6 billion by 2033, with a CAGR of 7.2% during the forecast period from 2024 to 2033.
The surge in demand for new advanced treatments and the rise in metabolic disorders and cancer are some of the main key driving factors for the peptide market. Peptides are tiny chains of amino acids that are connected by peptide bonds.
These are significantly tinier forms of proteins that consist of 50 or fewer amino acids. While some proteins and hormones play an essential role in our body’s functioning, peptides are substantial. They are present in different biological functions that comprise hormone production, cell signaling, and immune system activity.
According to the National Centre for Chronic Disease Prevention and Health Promotion (NCCDPHP), more than 1.7 million individuals are affected with cancer, and among that 600,000 die due to cancer, people spend $185 billion for cancer healthcare. Moreover, according to PubMed Central report in March 2023, there were approx. 14,61,427 cancer cases were reported in India for the year 2022. In India, 1 out of 9 individuals are likely to get affected with cancer in their lifespan.
The therapeutic capability of peptides underlays in their potentiality to impersonate the natural and original biological processes in our bodies. This signifies that they can be constructed to interfere with particular cellular functions, thus providing targeted treatment alternatives. Many studies have offered scientific proof supporting peptide therapy reliability as a new frontline in medical treatments. For example, peptides have displayed promise in cancer treatment by particularly targeting tumor cells without impacting any other healthy cells.
Peptide therapy provides several health benefits. One of the most substantial benefits is its targeted approach. As peptides are constructed to bind to particular cell receptors and provoke specific responses, they permit accurate medical treatment by reducing side effects. Moreover, these have also shown exceptional responses to anti-aging treatments. Research advises that certain peptides can arouse collagen production, enhancing skin elasticity and decreasing wrinkles.
Likewise, peptides such as BPC-157 have the potential to treat and heal tissue damage in the body. It is mainly used to treat musculoskeletal injuries. BPC-157 also helps in augmenting the healing procedure of bone fractures by promoting tissue regeneration and decreasing inflammation. The demand for the peptide will increase due to its medicinal advantages which will help in market expansion in the coming years.
Peptides Market Dynamics
Chronic Diseases Propel Peptides Market Growth
The market for peptides is experiencing significant growth factors due to the increasing prevalence of chronic illnesses. As per a 2023 study, the incidence of adults aged 50 and older with chronic diseases is set to nearly double by 2035. In the United States alone, 60% of adults are affected by a chronic condition, with 40% grappling with multiple ailments. This surge in chronic diseases such as diabetes, cancer, and cardiovascular disorders has amplified the demand for peptide-based therapeutics. For instance, Liraglutide, a GLP-1 peptide, is widely used in diabetes treatment, exemplifying the critical role of peptides in managing chronic conditions.
Advances in Peptide Synthesis Spur Market Expansion
Innovations in peptide synthesis technologies significantly impact the peptides market. Enhanced automated and efficient synthesis methods have lowered production costs and facilitated the creation of purer, more complex peptides. A notable example is Amide Technologies’ advancement in peptide drug design, which overcomes the limitations of traditional synthesis, allowing for longer peptide chains. This technological leap forward broadens the peptide drug applications, marking a pivotal shift in the market.
Oral Delivery Innovations Broaden Peptides’ Appeal
The progression in oral peptide delivery methods, including lipidation and permeation enhancers, is transforming the peptides market. These advancements make oral peptide therapeutics more practical, enhancing patient convenience and compliance. Recent breakthroughs have led to orally available cyclic peptides with significantly higher bioavailability, a monumental step for peptide-based biologics traditionally hindered by low oral bioavailability. This development opens new doors for peptide drug administration, making them more accessible and patient-friendly.
Short Half-Life Challenges Sustainment in Peptides Market
The inherently short half-life of peptides significantly limits their market growth rate. Unlike small molecules, peptides generally require more frequent dosing or advanced delivery methods to maintain their therapeutic effectiveness. For instance, the peptide drug liraglutide necessitates once-daily injection due to its 5-8 hour half-life. This characteristic poses logistical challenges both for patients in terms of adherence to treatment regimens and for manufacturers in developing formulations that ensure adequate duration of action. The need for frequent dosing or complex delivery systems can be a deterrent to both patient compliance and broader market acceptance.
Immunogenicity Concerns Impede Peptides Market Expansion
Immunogenicity poses a significant barrier to the market expansion of peptides. Therapeutic peptides carry the risk of provoking immune responses in patients, which can impact both the safety and efficacy of these treatments. This necessitates extensive screening assays to detect anti-drug antibodies, adding to the complexity and cost of development and post-market surveillance. The potential for immunogenic reactions can be a significant concern for both healthcare providers and patients, potentially limiting the adoption and use of peptide-based therapies. Such safety concerns need to be meticulously addressed to expand the peptides market effectively.
Peptides Market Segmentation Analysis
By Application Analysis
Metabolic Disorders represent the dominant segment in the peptides market with a 35.6% share. The prevalence of metabolic disorders, such as diabetes and obesity, has significantly increased, driving the demand for effective peptide-based treatments. Peptides play a crucial role in managing these disorders due to their specificity and efficacy in modulating metabolic processes. Insulin, a key peptide hormone, is essential for diabetes management, while other peptide-based therapies are being developed to target various aspects of metabolic disorders.
Other applications like the Cancer segment, Cardiovascular Disorders, Respiratory Disorders, and more also contribute to the market. Each of these areas benefits from the targeted and efficient nature of peptide therapies, but the widespread incidence of metabolic disorders and the central role of peptide treatments in their management underscore this segment's dominance.
By Type Analysis
Branded Peptides dominate the market with a 59.8% share. Branded peptides, often associated with novel therapeutic properties and patent protection, command higher prices and have significant R&D backing. The investment in developing branded peptides is driven by their potential to address unmet medical needs with higher specificity and reduced side effects compared to traditional small-molecule drugs.
Generic peptides, while also important, typically enter the market after the expiration of patents, offering more cost-effective alternatives. However, the innovation and exclusive market presence associated with branded peptides solidifies their dominant position.
By Type of Manufacturers Analysis
In-house Manufacturing leads the peptides market with a 60% share. Major pharmaceutical and biotech companies often prefer in-house manufacturing to maintain control over the quality, supply chain, and intellectual property of their peptide products. In-house facilities are equipped to handle the complex synthesis and purification processes required in peptide production.
Outsourced manufacturing, though significant, is often opted for by smaller companies or for specific processes that require specialized expertise. Despite this, the scale and control offered by in-house manufacturing underline its dominance in the market.
By Route of Administration Analysis
Parenteral Route is the most prevalent in the peptides market, holding an 85.6% share. This dominance is due to the nature of peptides, which often require parenteral administration to avoid degradation in the gastrointestinal tract. Parenteral routes, including intravenous, subcutaneous, and intramuscular injections, are essential for the effective delivery of many therapeutic peptides.
Oral, Pulmonary, Mucosal, Transdermal, and other routes are being developed to improve patient compliance and expand the application of peptide therapies. However, the current efficacy and necessity of parenteral administration for many peptide drugs make it the dominant route.
By Synthesis Technology Analysis
Liquid Phase Peptide Synthesis (LPPS) is the most popular synthesizer in the peptides market, holding 40% of the market.LPPS is esteemed for its effectiveness and scalability in manufacturing complex peptides. This technique allows producing large amounts of peptides. This is essential for commercial applications.
Solid Phase Peptide Synthesis (SPPS) and Hybrid Technology also contribute significantly. SPPS is preferred for its flexibility and precision in synthesizing a wide range of peptides, while Hybrid Technology combines the advantages of both solid and liquid phase methods. However, LPPS stands out as the most dominant competitor in the market, due to its capacity and efficacy in commercial production of Peptides.
Peptides Industry Segments
By Application
- Metabolic Disorders
- Cancer
- Cardiovascular Disorders
- Respiratory Disorders
- Gastrointestinal Disorders
- Infectious Diseases
- Dermatological Disorders
- Neurological Disorders
- Renal Disorders
- Others
By Type
- Branded
- Generic
By Type of Manufacturers
- In-house
- Outsourced
By Route of Administration
- Parenteral Route
- Oral Route
- Pulmonary
- Mucosal
- Transdermal
- Others
By Synthesis Technology
- Liquid Phase Peptide Synthesis (LPPS)
- Solid Phase Peptide Synthesis (SPPS)
- Hybrid Technology
Peptides Market Growth Opportunity
Expanding Peptide Drug Pipeline Unlocks New Horizons in the Peptides Market
The discovery of new Peptide drugs, especially to treat cancer, diabetes, and cardiovascular drug problems is a huge potential for growth in the market for peptides. These areas, characterized by high unmet medical needs and sizable market potential, are ripe for innovation. The success of peptide drugs such as liraglutide has catalyzed further research and development in this domain.
With an expanding pipeline of peptide drug candidates, the market is poised for substantial growth, driven by the promise of these novel therapeutics in addressing complex health conditions more effectively than traditional drugs.
Leveraging Peptides for Targeted Drug Delivery Enhances Market Potential
The use of peptides in targeted methods of drug delivery is an enormous growth opportunity for the market for peptides. Peptides can be engineered to deliver drugs specifically to targeted tissues or organs, thereby overcoming many of the challenges associated with traditional drug delivery methods. For example, the discovery of peptides that target tumors can revolutionize cancer treatment by increasing the effectiveness and precision of treatments.
This targeted approach not only enhances the therapeutic outcomes but also minimizes side effects, making peptide-based delivery systems highly attractive in the market. As such, leveraging peptides for targeted delivery is likely to drive significant advancements and market expansion in the field of precision medicine.
Peptides Market Regional Analysis
North America Dominates with 43.50% Market Share in Peptides Market
North America's commanding 43.50% share of the global peptides market is primarily driven by its advanced biotech sector and significant investments in pharmaceutical R&D. The United States, being a hub for biotechnological innovations, plays a pivotal role in this dominance. Factors contributing to this include high healthcare spending, a strong focus on research in therapeutic peptides, and a robust pipeline of peptide-based drugs. The presence of major pharmaceutical and biotech companies, which are leaders in peptide drug development, further bolsters the region's market share.
Within North America, the peptide market is characterized by rapid advances in both peptide synthesizers as well as delivery technology. The increasing prevalence of chronic diseases such as cancer and diabetes, where peptide-based treatments are showing promise, fuels the market growth. Additionally, the region's emphasis on targeted and personalized medicine has accelerated the demand for peptide therapeutics. The market also benefits from a well-established regulatory framework that supports innovation and ensures the safety and efficacy of peptide drugs.
Europe: Strong Research Infrastructure and Diverse Clinical Applications
Europe’s peptides market is driven by a strong research infrastructure and diverse clinical applications. Countries like Germany, the UK, and France are home to numerous biotech firms engaged in peptide research. The European market is further supported by favorable regulatory policies and a focus on developing novel peptide-based therapies.
Asia-Pacific: Rapid Market Growth and Increasing Healthcare Expenditure
The peptides market in Asia-Pacific is witnessing rapid growth, led by countries like China, Japan, and India. The region's market expansion is fueled by increasing healthcare expenditure, a growing biotech sector, and rising awareness of advanced therapeutic options. The rising prevalence of chronic diseases in the region also presents significant growth opportunities for peptide-based treatments.
Peptides Industry By Region
North America
- The US
- Canada
- Rest of North America
Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherlands
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Peptides Market Share Analysis
In the Peptides Market, a rapidly growing sector within the pharmaceutical industry, listed companies play a significant part in shaping the design and development of strategies for the commercialization of peptide-based therapies. Eli Lilly and Company and Novo Nordisk A/S are significant contributors, particularly noted for their advancements in insulin and glucagon-like peptide-1 (GLP-1) receptor agonists. Their strategic focus on diabetes and metabolic disorders significantly impacts the therapeutic landscape of peptide drugs.
Amgen Inc. and Bristol-Myers Squibb Company have made notable contributions to peptide therapeutics in oncology and cardiovascular diseases. Their commitment to innovation in peptide drug design and delivery systems underscores the market's evolution towards more targeted and effective treatments.
Peptides Industry Key Players
- Eli Lilly and Company
- Ipsen S.A
- Amgen Inc.
- Novo Nordisk A/S
- Bristol-Myers Squibb Company
- AstraZeneca plc Merck & Co. Inc
- GlaxoSmithKline PLC
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Novartis AG
Peptides Market Recent Development
- In Dec 2023, Ripple Pea Milk, a leading US plant-based milk brand, recently raised a substantial $49.2 million in its latest funding round, elevating the company’s total investments to a staggering $274 million. This financial boost coincides with a growing interest in the pea milk category, which has recently overshadowed the broader alt-dairy sector in year-on-year growth.
- In Sept 2023, Contract Development and Manufacturing Organisation (CDMO) CordenPharma committed over €200 million ($215 million) in 2023 to expand its global peptide, lipids, and injectables capacity. Among the investments, CordenPharma made a $60 million investment into its facility in Boulder, Colorado to support a multi-year agreement for the contract manufacturing of a large-volume commercial peptide.
- In 2023, Bachem Group (SIX: BANB) announced that it had signed a new framework agreement to provide large volumes of peptides following a joint development project. Manufacturing is to primarily occur at Bachem’s new large-scale production facility (Building “K”) currently under construction in Bubendorf. The order covers a committed volume at an equivalent value of over CHF 500 million for five years.
- In Aug 2023, EUROAPI and the shareholders of BianoGMP (“Biano”), a Contract Development and Manufacturing Organization (“CDMO”), with recognized expertise in oligonucleotides, signed a share purchase and transfer agreement under which EUROAPI will acquire 100% of Biano shares. The total consideration for the transaction is approximately €10M, including the acquisition price.
Report Scope
Report Features Description Market Value (2023) USD 45.5 Billion Forecast Revenue (2033) USD 89.6 Billion CAGR (2024-2032) 7.2% Base Year for Estimation 2023 Historic Period 2016-2023 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Application(Metabolic Disorders, Cancer, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Dermatological Disorders, Neurological Disorders, Renal Disorders, Others), By Type(Branded, Generic), By Type of Manufacturers(In-house, Outsourced), By Route of Administration(Parenteral Route, Oral Route, Pulmonary, Mucosal, Transdermal, Others), By Synthesis Technology(Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), Hybrid Technology) Regional Analysis North America - The US, Canada, Rest of North America, Europe - Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe, Asia-Pacific - China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of Asia Pacific, Latin America - Brazil, Mexico, Rest of Latin America, Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Competitive Landscape Eli Lilly and Company, Ipsen S.A, Amgen Inc., Novo Nordisk A/S, Bristol-Myers Squibb Company, AstraZeneca plc Merck & Co. Inc, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd. Takeda Pharmaceutical Company Limited, Novartis AG Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
-
- Eli Lilly and Company
- Ipsen S.A
- Amgen Inc.
- Novo Nordisk A/S
- Bristol-Myers Squibb Company
- AstraZeneca plc Merck & Co. Inc
- GlaxoSmithKline PLC
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Novartis AG